



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: **Acumapimod**  
产品别名: **Acumapimod**

<b>生物活性:</b>				
<b>Description</b>	Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC <sub>50</sub> of less than 1 $\mu$ M for p38 $\alpha$ .			
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : less than 1 $\mu$ M (p38 $\alpha$ )[1]			
<b>In Vitro</b>	Acumapimod is an inhibitor of p38 $\alpha$ with an IC <sub>50</sub> value of less than 1 $\mu$ M.			
<b>In Vivo</b>	BCT197 is an oral low-molecular-weight p38 inhibitor currently in development for the treatment of several inflammatory conditions, including chronic obstructive pulmonary disease (COPD). Intermittent short-term dosing of BCT197 (75 mg on days 1 and 6) shows a marked improvement in lung function in COPD patients[2].			
<b>Solvent&amp;Solubility</b>	<b><i>In Vitro:</i></b> <b>DMSO : <math>\geq</math> 50 mg/mL (129.73 mM)</b> <small>* "<math>\geq</math>" means soluble, but saturation unknown.</small>			
	<b>Preparing Stock Solutions</b>	<b>Solvent / Mass Concentration</b>	<b>1 mg</b>	<b>5 mg</b>
		1 mM	2.5946 mL	12.9729 mL
		5 mM	0.5189 mL	2.5946 mL
		10 mM	0.2595 mL	1.2973 mL
	<b>10 mg</b>			
	25.9457 mL			
	5.1891 mL			
	2.5946 mL			
	<b>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液: 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</b>			
	<b>储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</b>			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>3.请依序添加每种溶剂: 10% DMSO →90% corn oil</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (6.49 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (6.49 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
References	<p>[1]. Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.</p> <p>[2]. De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700.</p>

源叶生物